| Drug Name |
Epirubicin hydrochloride |
| Drug ID |
BADD_D00785 |
| Description |
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. |
| Indications and Usage |
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
L01DB03 |
| DrugBank ID |
DB00445
|
| KEGG ID |
D02214
|
| MeSH ID |
D015251
|
| PubChem ID |
65348
|
| TTD Drug ID |
D0C9XJ
|
| NDC Product Code |
77391-002; 0009-5093; 0143-9202; 0009-5091; 59923-701; 0143-9203; 27831-002 |
| Synonyms |
Epirubicin | 4'-Epidoxorubicin | 4' Epidoxorubicin | 4'-Epi-Doxorubicin | 4' Epi Doxorubicin | 4'-Epi-Adriamycin | 4' Epi Adriamycin | 4'-Epiadriamycin | 4' Epiadriamycin | 4'-Epi-DXR | 4' Epi DXR | EPI-cell | EPI cell | EPIcell | Epilem | Farmorubicina | IMI-28 | IMI 28 | IMI28 | NSC-256942 | NSC 256942 | NSC256942 | Ellence | Pharmorubicin | Farmorubicine | Farmorubicin | Epirubicin Hydrochloride | Hydrochloride, Epirubicin |
